- Home
- ATOS vs FLC Comparison
ATOS vs FLC Comparison
Compare ATOS & FLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- FLC
- Stock Information
- Founded
- ATOS 2009
- FLC 2003
- Country
- ATOS United States
- FLC United States
- Employees
- ATOS N/A
- FLC N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- FLC Trusts Except Educational Religious and Charitable
- Sector
- ATOS Health Care
- FLC Finance
- Exchange
- ATOS Nasdaq
- FLC Nasdaq
- Market Cap
- ATOS 174.8M
- FLC 180.6M
- IPO Year
- ATOS 2012
- FLC N/A
- Fundamental
- Price
- ATOS $1.19
- FLC $16.50
- Analyst Decision
- ATOS Strong Buy
- FLC
- Analyst Count
- ATOS 3
- FLC 0
- Target Price
- ATOS $6.75
- FLC N/A
- AVG Volume (30 Days)
- ATOS 738.2K
- FLC 37.8K
- Earning Date
- ATOS 11-12-2024
- FLC 01-01-0001
- Dividend Yield
- ATOS N/A
- FLC 6.64%
- EPS Growth
- ATOS N/A
- FLC N/A
- EPS
- ATOS N/A
- FLC N/A
- Revenue
- ATOS N/A
- FLC N/A
- Revenue This Year
- ATOS N/A
- FLC N/A
- Revenue Next Year
- ATOS N/A
- FLC N/A
- P/E Ratio
- ATOS N/A
- FLC N/A
- Revenue Growth
- ATOS N/A
- FLC N/A
- 52 Week Low
- ATOS $0.70
- FLC $12.62
- 52 Week High
- ATOS $2.31
- FLC $15.45
- Technical
- Relative Strength Index (RSI)
- ATOS 31.91
- FLC 33.24
- Support Level
- ATOS $1.26
- FLC $16.55
- Resistance Level
- ATOS $1.66
- FLC $16.70
- Average True Range (ATR)
- ATOS 0.09
- FLC 0.15
- MACD
- ATOS -0.03
- FLC -0.04
- Stochastic Oscillator
- ATOS 4.08
- FLC 6.76
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.